for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sosei Group Corporation

4565.T

Latest Trade

2,106.00JPY

Change

-23.00(-1.08%)

Volume

781,600

Today's Range

2,061.00

 - 

2,135.00

52 Week Range

985.00

 - 

2,794.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Sosei Heptares And Takeda Enter Into New Partnership

Aug 5 (Reuters) - Sosei Group Corp <4565.T>::SOSEI HEPTARES AND TAKEDA ENTER INTO NEW STRATEGIC MULTI-TARGET RESEARCH, DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP.CO IS ELIGIBLE TO RECEIVE UP TO $26 MILLION IN UPFRONT, NEAR-TERM PAYMENTS, IN ADDITION TO RESEARCH FUNDING OVER AGREEMENT TERM.

Sosei Heptares Says Marketing Application For Asthma Therapy Has Been Filed With EMA

May 24 (Reuters) - Sosei Group Corp <4565.T>::SOSEI HEPTARES NOTES THAT A VALID MARKETING AUTHORIZATION APPLICATION FOR QVM149, A POTENTIAL NEW INHALED COMBINATION THERAPY FOR ASTHMA, HAS BEEN FILED WITH EUROPEAN MEDICINES AGENCY.MAA FILING HAS TRIGGERED A $2.5 MILLION PAYMENT TO SOSEI HEPTARES FROM NOVARTIS.

Sosei Group Says Sosei Heptares To Get US$15 Mln Milestone Payment From Astrazeneca

Jan 7 (Reuters) - Sosei Group Corp <4565.T>::NOTIFIED BY ASTRAZENECA IT REACHED CLINICAL DEVELOPMENT MILESTONE WITH PARTNERED NEXT GENERATION IMMUNO-ONCOLOGY CANDIDATE AZD4635.SOSEI HEPTARES TO GET US$15 MILLION MILESTONE PAYMENT FROM ASTRAZENECA WITH FIRST PARTNERED PROGRAM MOVING TOWARDS PHASE 2.

Sosei announces approval of ORAVI Mucoadhesive tablets 50mg for Oropharyngeal Candidiasis in Japan

Sept 25(Reuters) - Sosei Group Corp <4565.T>:Says its wholly-owned Japanese subsidiary Sosei Co., Ltd., has received the approval in Japan for ORAVI ® Mucoadhesive Tablets 50mg.

Sosei Group says change of corporate auditor

May 16 (Reuters) - Sosei Group Corp <4565.T>:Says it appoints Ernst & Young ShinNihon LLC as new corporate auditor, to replace Deloitte Touche Tohmatsu LLC , effective June 22 .

Sosei Says Does Not Intend To Make An Offer For Vectura

April 24 (Reuters) - Sosei Group Corp::STATEMENT RE PRESS COMMENT.CONFIRMS THAT IT DOES NOT INTEND TO MAKE AN OFFER FOR VECTURA.SOSEI WILL, EXCEPT WITH CONSENT OF UK PANEL ON TAKEOVERS AND MERGERS, BE BOUND BY RESTRICTIONS CONTAINED IN RULE 2.8 OF CODE.

Sosei Group regains worldwide rights from Teva to develop and commercialize novel small molecule CGRP antagonists for migraine and other severe headaches

March 13 (Reuters) - Sosei Group Corp <4565.T>:Says co has regained worldwide rights from Teva Pharmaceutical Industries Ltd., to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches.

Sosei Group says new share prices

Nov 20 (Reuters) - Sosei Group Corp <4565.T>:Says it will issue new shares of its common stock via overseas offering, with the issue price of 10,800 yen per share (22.36 billion yen in total) and paid-in price of 10,283.55 yen per share (21.29 billion yen in total).Says payment date on Nov. 27.Previous news was disclosed on Nov. 10.

Sosei Group to issue 2.1 mln new shares

Nov 10(Reuters) - Sosei Group Corp <4565.T>:Says it plans to issue 2.1 million new shares through overseas offering .Proceeds to be mainly used for drug discovery and research and development related fund .

Sosei Group to advance clinical development in Japan of HTL0018318 in patients with Dementia with Lewy Bodies (DLB)

Nov 9(Reuters) - Sosei Group Corp <4565.T>:Says it gains a licence to develop and commercialise HTL0018318, a novel muscarinic M1 receptor agonist, in Japan as a potential new treatment for patients with dementia with Lewy bodies (DLB).Says it will undertake a Phase 2 proof-of-concept monotherapy study, expected to begin in Japan in 2018 .

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up